Advertisement

The Events Group Pharm Connect Congress 2015 Budapest February 600x60px
Document › Details

4-Antibody AG. (3/16/10). "Press Release: 4-Antibody Announces Long-term Collaboration with Boehringer Ingelheim for Therapeutic Antibodies". Basel.

Organisations Organisation 4-Antibody AG
  Group Agenus (Group)
  Organisation 2 Boehringer Ingelheim (Group)
Products Product antibody technology
  Product 2 MAb, human, fully
Index term Index term Boehringer–4-Antibody: therapeutic antibodies, 201003– collab up to €177.5m incl upfront + milestones discovery + developm fully human antibodies
Person Person Grawunder, Ulf (4-Antibody 200810 CSO before CEO + founder)
     


4-Antibody AG today announces a major long-term collaboration with Boehringer Ingelheim to discover and to develop fully human therapeutic antibodies for a number of targets in various disease indications. 4-Antibody will use its proprietary and unencumbered Hu-PAC® and Retrocyte Display® technologies for the discovery and development of fully human antibodies against novel targets nominated by Boehringer Ingelheim. 4-Antibody AG will receive payments of up to EUR 177.5 million (CHF 266 million) including upfront and milestone payments from Boehringer Ingelheim upon achievement of certain clinical development milestones. Further financial details were not disclosed.

Dr. Ulf Grawunder, co-founder and CSO of 4-Antibody AG, said “This is a landmark agreement for 4-Antibody. We are delighted to commence a long-term collaboration with Boehringer Ingelheim and to apply the strength of 4-Antibody’s fully human antibody discovery and engineering platforms to create valuable potential new drug candidates. Our unique and unencumbered technology capabilities allow the efficient generation of novel or improved fully human antibodies against any target class for our collaboration partners and for our own clinical development pipeline.”

- ends -

About 4-Antibody AG

4-Antibody AG is a privately held Swiss Biotech company active in the area of therapeutic
antibody drug development. 4-Antibody AG has developed a portfolio of powerful, proprietary
antibody discovery and engineering platforms, including the Hu-PAC® and the Retrocyte Display® technologies. 4-Antibody AG owns four patent families related to therapeutic antibody discovery platforms and products, including more than a dozen of granted patents worldwide. The company has 40 employees working at its headquarter in Basel, Switzerland, and its subsidiary in Jena, Germany.

   
Record changed: 2014-04-24

Advertisement

Banner Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for Agenus (Group)


To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to info@iito.de and simply fill the subject line with the word »LSG newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Banner Fairtec GmbH We Optimise the ROI of Your Event 600x60px




» top

Advertisements

Banner EBD Group BIO Europe 2013 BEU Frankfurt November 120x180px Highl Successful LC/MS Niche Player Is Looking for a Junior Partner 120x240px The Events Group Pharm Connect Congress 2015 Budapest February 120x180px Banner C5 Communications Life Sciences IP Summit 2014 Amsterdam 120x180px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Banner [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px